Literature DB >> 10608728

A case of factor VIII inhibitor-positive acquired hemophilia treated by plasmapheresis.

N Narukawa1, T Abe, M Shouno, Y Kitabata, M Okamoto, H Kobata, T Akizawa.   

Abstract

We report on a case of factor VIII inhibitor-positive acquired hemophilia in which combined therapy of plasma exchange (PE) and steroids was effective. The patient, a 68-year-old man, had undergone hemodialysis since April 1998, due to chronic renal failure caused by diabetic nephropathy. The hemostasis of blood access sites gradually became difficult after the initiation of dialysis and the prolongation of activated partial thromboplastin time (APTT) (74.5 s), and a decrease in factor VIII (0.02%) and an abnormally high concentration of factor VIII inhibitor (111 U/ml) were found. Under the diagnosis of factor VIII inhibitor-positive acquired hemophilia, 3 consecutive PE were performed, followed by a large dose administration of gamma globulin. However, the effect of this therapy disappeared within 20 days. Then the PE therapy was performed again accompanied by pulse methylprednisolone therapy. After that, factor VIII inhibitor was suppressed and the patient's hemostatic defect continued to improve even after the reduction of the steroid dose. These results suggest that PE is very effective in treating factor VIII inhibitor-positive acquired hemophilia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10608728     DOI: 10.1046/j.1526-0968.1999.00212.x

Source DB:  PubMed          Journal:  Ther Apher        ISSN: 1091-6660


  2 in total

1.  Renal hemorrhage caused by acquired inhibitors to coagulation factors VIII and V in a hemodialysis patient.

Authors:  Naoya Niwa; Tadashi Yoshida; Ryuichi Mizuno; Mototsugu Oya; Matsuhiko Hayashi
Journal:  CEN Case Rep       Date:  2016-07-25

2.  Hemarthrosis as acute presentation of acquired hemophilia in a patient with systemic lupus erythematosus: successful treatment and long-lasting remission.

Authors:  G Porru; V Mura; M Piga; V Ibba; A Vacca; A Cauli; G Passiu; R Targhetta; F Marongiu; A Mathieu
Journal:  Clin Rheumatol       Date:  2008-09-27       Impact factor: 2.980

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.